Abstract
B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.
| Original language | English |
|---|---|
| Pages (from-to) | 229-231 |
| Number of pages | 3 |
| Journal | Journal of Neuroimmunology |
| Volume | 276 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - Nov 15 2014 |
Keywords
- B lymphocytes
- CD20
- Neurodegeneration
ASJC Scopus subject areas
- Immunology
- Clinical Neurology
- Immunology and Allergy
- Neurology
- Medicine(all)
Fingerprint Dive into the research topics of 'Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis'. Together they form a unique fingerprint.
Cite this
Studer, V., Rossi, S., Motta, C., Buttari, F., & Centonze, D. (2014). Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. Journal of Neuroimmunology, 276(1-2), 229-231. https://doi.org/10.1016/j.jneuroim.2014.08.617